EGFR and lung adenocarcinoma: Clinical trials are currently underway to assess the efficacy of novel molecular‐targeted drugs or immune checkpoint inhibitors in EGFR‐mutated lung adenocarcinoma patients with T790M‐negative or with an unknown mutation.29